Literature DB >> 19645612

Genetic-targeted therapy of thyroid cancer: a real promise.

Mingzhao Xing.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19645612     DOI： 10.1089/thy.2009.1583

Source DB:  PubMed          Journal:  Thyroid        ISSN： 1050-7256            Impact factor:   6.568


× No keyword cloud information.
  9 in total

1.  The BRAFT1799A mutation confers sensitivity of thyroid cancer cells to the BRAFV600E inhibitor PLX4032 (RG7204).

Authors:  Joanna Xing; Ruixin Liu; Mingzhao Xing; Barry Trink
Journal:  Biochem Biophys Res Commun       Date:  2010-12-23       Impact factor: 3.575

2.  The Akt-specific inhibitor MK2206 selectively inhibits thyroid cancer cells harboring mutations that can activate the PI3K/Akt pathway.

Authors:  Ruixin Liu; Dingxie Liu; Eliana Trink; Ermal Bojdani; Guang Ning; Mingzhao Xing
Journal:  J Clin Endocrinol Metab       Date:  2011-02-02       Impact factor: 5.958

3.  Identifying genetic alterations in poorly differentiated thyroid cancer: a rewarding pursuit.

Authors:  Mingzhao Xing
Journal:  J Clin Endocrinol Metab       Date:  2009-12       Impact factor: 5.958

4.  Current concepts and future directions in differentiated thyroid cancer.

Authors:  Donald S A McLeod
Journal:  Clin Biochem Rev       Date:  2010-02

Review 5.  Genetic alterations in the phosphatidylinositol-3 kinase/Akt pathway in thyroid cancer.

Authors:  Mingzhao Xing
Journal:  Thyroid       Date:  2010-07       Impact factor: 6.568

6.  The Akt inhibitor MK2206 synergizes, but perifosine antagonizes, the BRAF(V600E) inhibitor PLX4032 and the MEK1/2 inhibitor AZD6244 in the inhibition of thyroid cancer cells.

Authors:  Ruixin Liu; Dingxie Liu; Mingzhao Xing
Journal:  J Clin Endocrinol Metab       Date:  2011-11-16       Impact factor: 5.958

Review 7.  Molecular pathogenesis and mechanisms of thyroid cancer.

Authors:  Mingzhao Xing
Journal:  Nat Rev Cancer       Date:  2013-03       Impact factor: 60.716

8.  Thyroid cancer cell lines: Critical models to study thyroid cancer biology and new therapeutic targets.

Authors:  Rebecca E Schweppe
Journal:  Front Endocrinol (Lausanne)       Date:  2012-06-19       Impact factor: 5.555

9.  B-Raf mutation and papillary thyroid carcinoma patients.

Authors:  Lixin Jiang; Haidi Chu; Haitao Zheng
Journal:  Oncol Lett       Date:  2016-03-01       Impact factor: 2.967
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.